Developer docs
API playgroundTry for free, no card

Search company profiles

Delta4

Full company profile

uuid00095js

Namestring
Delta4
Legal namestring
Delta4 GmbH
Websiteurl
delta4.ai
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Delta4 GmbH is a Vienna-based TechBio company founded in 2018 that builds AI-powered computational tools for drug indication expansion. The company's core product is Hyper-C, a proprietary platform that combines systems biology, computational modeling, artificial intelligence, and large-scale data analysis to detect previously unrecognized relationships between drugs with known safety profiles and new therapeutic indications. Hyper-C is operated by a team of computational biologists who interpret AI-generated insights to identify drug repurposing and indication expansion opportunities, targeting complex and rare diseases where traditional de novo drug discovery is slow and expensive.

Delta4 operates a professional services / enterprise engagement model, applying its in-silico models directly to client drug and indication programs. Customers apply to work with Delta4 through its Services and Partnering pages, and the company sells primarily to pharmaceutical and biotech firms across Europe, with a stated global footprint. Named clients and partners include Takeda, Biogen, Calliditas Therapeutics, Gerot Lannach, 4P Pharma, two undisclosed "Top Pharma" firms in Germany and Scandinavia, and Austrian academic institutions Medizinische Universität Innsbruck and Medizinische Universität Wien. Distribution runs through direct enterprise sales, supplemented by a featured profile on Scientist.com, a marketplace used by pharma research buyers.

The company is privately held with 11-50 employees, headquartered in Purkersdorf, Austria, and led by founder and CEO Kurt Herpel. Only one early-stage funding round is recorded (April 2021, amount undisclosed). Strategic positioning is reinforced by recognition from the Austrian Research Promotion Agency (FFG) and active participation in European biotech industry events such as Bio€quity Europe 2026. Delta4 has not disclosed revenue, patents, headcount growth, or formal funding to date, limiting external visibility into its commercial scale.

Short descriptiontext

Delta4 is an Austrian TechBio company whose proprietary Hyper-C AI platform identifies new therapeutic indications for existing drugs with known safety profiles, serving pharmaceutical, biotech, and academic clients across Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVienna, Austria
HQ citystring
Vienna
HQ countrystring
Austria
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, computational biology, drug repurposing, indication expansion, in-silico modeling
Industry1 code
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI Drug Discovery & Indication Expansion
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Discovery Services
TypeProfessional Services
Description

Delta4 offers in-silico modeling services to pharmaceutical and biotech clients, applying their Hyper-C AI platform to accelerate drug and indication programs. The company operates on a services/retainer model, inviting prospective clients to 'Apply our in-silico models to accelerate your drug or indication program.' Revenue is derived from service fees charged to pharma clients seeking indication expansion for existing drugs.

delta4.ai
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Hyper-C
Description

Proprietary AI-powered platform used by Delta4 to detect undetected relationships between drugs with known safety profiles to identify new therapeutic indications. Operated by computational biologists to produce unique insights and detect drug indication expansion opportunities.

delta4.ai
Core offering1 text field

Delta4 operates Hyper-C, a proprietary AI-powered computational platform that combines systems biology, computational modeling, and large-scale data analysis to detect undetected relationships between drugs with known safety profiles and identify new therapeutic indications. The company delivers this capability as in-silico drug discovery and indication expansion services to pharmaceutical and biotech clients, applying the platform to accelerate their drug or indication programs.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Delta4 is a TechBio company with a single unified core product offering: the Hyper-C platform. This AI-powered computational platform enables pharmaceutical clients to discover new therapeutic uses for existing drugs by analyzing complex biological data and identifying drug-disease relationships. The platform is operated by a team of computational biologists who interpret AI-generated insights to detect drug indication expansion opportunities, helping get new treatment options to market faster, more cost-effectively, and more safely than traditional drug development approaches.

Product and service3 records
1Hyper-C Platform
CategoryAI Drug Discovery Software Platform
Description

Proprietary AI-powered platform that combines systems biology, computational modeling, artificial intelligence, and large-scale data analysis to detect undetected relationships between drugs with known safety profiles and identify new therapeutic indications. Operated by skilled computational biologists and applied to accelerate pharmaceutical and biotech drug or indication programs.

2In-Silico Drug Discovery & Indication Expansion Services
CategoryDrug Discovery Services
Description

Professional services applying Delta4's Hyper-C platform to pharmaceutical and biotech clients' drug or indication programs, identifying new therapeutic indications for existing drugs with known safety profiles and accelerating drug development.

3Partnering & Co-Development Programs
CategoryDrug Discovery Partnering
Description

Collaboration programs enabling pharmaceutical, biotech, and academic partners to work with Delta4 on joint research, co-development, or consortia projects leveraging the Hyper-C platform for indication expansion and drug discovery.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1Austrian Research Promotion Agency (FFG)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Delta4 was featured by the Austrian Research Promotion Agency (FFG) for their work advancing computational biology. The FFG recognition highlights Delta4's role in connecting expertise, fostering young talent, and leveraging data-driven innovation to improve patient outcomes in Austria's biotech ecosystem.

delta4.ai
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Delta4 is a proud member of Scientist.com, a platform that streamlines transparency and cooperation between researchers and suppliers. The platform provides a collaboration framework to streamline the typically long process of defining terms and conditions for agreements. Delta4's AI-Powered Hyper-C Platform was featured on Scientist.com for uncovering new drug indications for Iguratimod.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Top Pharma (Germany) is listed as one of Delta4's partners and clients, working with Delta4 on drug discovery and indication expansion programs.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Top Pharma (Scandinavia) is listed as one of Delta4's partners and clients, working with Delta4 on drug discovery and indication expansion programs.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

4P Pharma is listed as one of Delta4's partners and clients in the pharmaceutical sector, collaborating on drug indication expansion.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Biogen is listed as one of Delta4's partners and clients in the biotech sector, collaborating on drug discovery programs.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Calliditas Therapeutics is listed as one of Delta4's partners and clients, working with Delta4 on drug discovery and indication expansion.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Gerot Lannach is listed as one of Delta4's pharmaceutical partners and clients, collaborating on drug indication programs.

9Medizinische Universität Innsbruck
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Medizinische Universität Innsbruck is listed as one of Delta4's partners, representing an academic collaboration in the Austrian biotech and pharmaceutical research ecosystem.

delta4.ai
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Medizinische Universität Wien is listed as one of Delta4's partners, representing an academic collaboration in computational biology and drug discovery research.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Takeda is listed as one of Delta4's pharmaceutical partners and clients, collaborating on drug discovery and indication expansion programs.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BenevolentAI is a London-based AI drug discovery company that uses machine learning on biomedical knowledge graphs to identify new therapeutic indications and drug-disease relationships — directly comparable to Delta4's Hyper-C platform and indication-expansion focus.

TypeDirect peer
Description

Schrödinger provides a physics-based computational platform for molecular simulation, drug discovery, and prediction of drug properties; it competes head-to-head with Hyper-C for pharma's in-silico discovery and indication expansion budgets.

TypeDirect peer
Description

Recursion combines high-throughput biology with AI/ML to discover new therapeutics and indications at scale — a directly comparable AI-driven drug discovery platform targeting similar pharma partnerships.

TypeDirect peer
Description

Exscientia is an AI-driven pharma company using precision design to accelerate small-molecule drug discovery and indication expansion, offering overlapping value proposition and enterprise pharma client base to Delta4.

TypeDirect peer
Description

Insitro combines ML with high-throughput experimental biology to discover therapeutics and predict drug behavior — competing for the same enterprise pharma AI-discovery partnerships as Delta4.

TypeDirect peer
Description

Atomwise applies deep learning to structure-based drug design and indication prediction, with a heavy pharma partnership focus; directly comparable to Hyper-C's in-silico approach.

7Isomorphic Labs
TypeBroad incumbent
Description

Isomorphic Labs (Alphabet-owned) builds AI-first drug discovery platforms and partners with major pharma like Novartis and Lilly; a well-capitalized broader incumbent operating in the same AI drug discovery space as Delta4.

TypeDirect peer
Description

Valo Health uses AI and patient data to accelerate drug discovery and indication expansion across therapeutic areas, overlapping closely with Delta4's platform-driven pharma services model.

TypeEmerging player
Description

Cyclica is a Toronto-based AI drug discovery company applying proteome-wide and polypharmacology approaches to drug repurposing and indication expansion — an emerging player with comparable technology positioning.

TypeEmerging player
Description

Owkin applies AI to biomedical research and clinical data for pharma and biotech clients, with partial overlap to Delta4's AI-driven drug discovery and disease-mechanism analysis capabilities.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Delta4

AI Drug Discovery & Indication Expansiondelta4.ai

Delta4 is an Austrian TechBio company whose proprietary Hyper-C AI platform identifies new therapeutic indications for existing drugs with known safety profiles, serving pharmaceutical, biotech, and academic clients across Europe.

What Delta4 does

Delta4 GmbH is a Vienna-based TechBio company founded in 2018 that builds AI-powered computational tools for drug indication expansion. The company's core product is Hyper-C, a proprietary platform that combines systems biology, computational modeling, artificial intelligence, and large-scale data analysis to detect previously unrecognized relationships between drugs with known safety profiles and new therapeutic indications. Hyper-C is operated by a team of computational biologists who interpret AI-generated insights to identify drug repurposing and indication expansion opportunities, targeting complex and rare diseases where traditional de novo drug discovery is slow and expensive.

Delta4 operates a professional services / enterprise engagement model, applying its in-silico models directly to client drug and indication programs. Customers apply to work with Delta4 through its Services and Partnering pages, and the company sells primarily to pharmaceutical and biotech firms across Europe, with a stated global footprint. Named clients and partners include Takeda, Biogen, Calliditas Therapeutics, Gerot Lannach, 4P Pharma, two undisclosed "Top Pharma" firms in Germany and Scandinavia, and Austrian academic institutions Medizinische Universität Innsbruck and Medizinische Universität Wien. Distribution runs through direct enterprise sales, supplemented by a featured profile on Scientist.com, a marketplace used by pharma research buyers.

The company is privately held with 11-50 employees, headquartered in Purkersdorf, Austria, and led by founder and CEO Kurt Herpel. Only one early-stage funding round is recorded (April 2021, amount undisclosed). Strategic positioning is reinforced by recognition from the Austrian Research Promotion Agency (FFG) and active participation in European biotech industry events such as Bio€quity Europe 2026. Delta4 has not disclosed revenue, patents, headcount growth, or formal funding to date, limiting external visibility into its commercial scale.

Delta4 firmographics

Firmographics
Name
Delta4
Legal name
Delta4 GmbH
Website
https://delta4.ai
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Delta4 is an Austrian TechBio company whose proprietary Hyper-C AI platform identifies new therapeutic indications for existing drugs with known safety profiles, serving pharmaceutical, biotech, and academic clients across Europe.
Ownership category
akta.pro rank

Delta4 industry classification

Industry
Product category
AI Drug Discovery & Indication Expansion
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Computational biology
  • Drug repurposing
  • Indication expansion
  • In-silico modeling

Where Delta4 is headquartered

Location

Headquarters

HQ city
Vienna
HQ country
Austria
HQ region
Europe

Offices1 record

Markets served

Delta4 business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Drug Discovery Services: Delta4 offers in-silico modeling services to pharmaceutical and biotech clients, applying their Hyper-C AI platform to accelerate drug and indication programs. The company operates on a services/retainer model, inviting prospective clients to 'Apply our in-silico models to accelerate your drug or indication program.' Revenue is derived from service fees charged to pharma clients seeking indication expansion for existing drugs.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Delta4 product offering

Product offering

Core offering

Delta4 operates Hyper-C, a proprietary AI-powered computational platform that combines systems biology, computational modeling, and large-scale data analysis to detect undetected relationships between drugs with known safety profiles and identify new therapeutic indications. The company delivers this capability as in-silico drug discovery and indication expansion services to pharmaceutical and biotech clients, applying the platform to accelerate their drug or indication programs.

Product overview

Delta4 is a TechBio company with a single unified core product offering: the Hyper-C platform. This AI-powered computational platform enables pharmaceutical clients to discover new therapeutic uses for existing drugs by analyzing complex biological data and identifying drug-disease relationships. The platform is operated by a team of computational biologists who interpret AI-generated insights to detect drug indication expansion opportunities, helping get new treatment options to market faster, more cost-effectively, and more safely than traditional drug development approaches.

Differentiator

Problem solved

Functional benefit

Brands

  • Hyper-C: Proprietary AI-powered platform used by Delta4 to detect undetected relationships between drugs with known safety profiles to identify new therapeutic indications. Operated by computational biologists to produce unique insights and detect drug indication expansion opportunities.

Products and services

  • Hyper-C Platform Proprietary AI-powered platform that combines systems biology, computational modeling, artificial intelligence, and large-scale data analysis to detect undetected relationships between drugs with known safety profiles and identify new therapeutic indications. Operated by skilled computational biologists and applied to accelerate pharmaceutical and biotech drug or indication programs.
  • In-Silico Drug Discovery & Indication Expansion Services Professional services applying Delta4's Hyper-C platform to pharmaceutical and biotech clients' drug or indication programs, identifying new therapeutic indications for existing drugs with known safety profiles and accelerating drug development.
  • Partnering & Co-Development Programs Collaboration programs enabling pharmaceutical, biotech, and academic partners to work with Delta4 on joint research, co-development, or consortia projects leveraging the Hyper-C platform for indication expansion and drug discovery.

Companies that use Delta4

Customer profile

Named customers9 records

Segments1 record

Ideal customer profiles2 records

Delta4 technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature1 record

Delta4 partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • Austrian Research Promotion Agency (FFG)coreStrategic or Co-development PartnerDelta4 was featured by the Austrian Research Promotion Agency (FFG) for their work advancing computational biology. The FFG recognition highlights Delta4's role in connecting expertise, fostering young talent, and leveraging data-driven innovation to improve patient outcomes in Austria's biotech ecosystem.
  • Scientist.comcoreStrategic or Co-development PartnerDelta4 is a proud member of Scientist.com, a platform that streamlines transparency and cooperation between researchers and suppliers. The platform provides a collaboration framework to streamline the typically long process of defining terms and conditions for agreements. Delta4's AI-Powered Hyper-C Platform was featured on Scientist.com for uncovering new drug indications for Iguratimod.
  • Top Pharma (Germany)minorStrategic or Co-development PartnerTop Pharma (Germany) is listed as one of Delta4's partners and clients, working with Delta4 on drug discovery and indication expansion programs.
  • Top Pharma (Scandinavia)minorStrategic or Co-development PartnerTop Pharma (Scandinavia) is listed as one of Delta4's partners and clients, working with Delta4 on drug discovery and indication expansion programs.
  • 4P PharmaminorStrategic or Co-development Partner4P Pharma is listed as one of Delta4's partners and clients in the pharmaceutical sector, collaborating on drug indication expansion.
  • BiogenminorStrategic or Co-development PartnerBiogen is listed as one of Delta4's partners and clients in the biotech sector, collaborating on drug discovery programs.
  • Calliditas TherapeuticsminorStrategic or Co-development PartnerCalliditas Therapeutics is listed as one of Delta4's partners and clients, working with Delta4 on drug discovery and indication expansion.
  • Gerot LannachminorStrategic or Co-development PartnerGerot Lannach is listed as one of Delta4's pharmaceutical partners and clients, collaborating on drug indication programs.
  • Medizinische Universität InnsbruckminorStrategic or Co-development PartnerMedizinische Universität Innsbruck is listed as one of Delta4's partners, representing an academic collaboration in the Austrian biotech and pharmaceutical research ecosystem.
  • Medizinische Universität WienminorStrategic or Co-development PartnerMedizinische Universität Wien is listed as one of Delta4's partners, representing an academic collaboration in computational biology and drug discovery research.
  • TakedaminorStrategic or Co-development PartnerTakeda is listed as one of Delta4's pharmaceutical partners and clients, collaborating on drug discovery and indication expansion programs.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Delta4 competitors and assessment

Company assessment

Direct peers

  • BenevolentAI: BenevolentAI is a London-based AI drug discovery company that uses machine learning on biomedical knowledge graphs to identify new therapeutic indications and drug-disease relationships — directly comparable to Delta4's Hyper-C platform and indication-expansion focus.
  • Schrödinger: Schrödinger provides a physics-based computational platform for molecular simulation, drug discovery, and prediction of drug properties; it competes head-to-head with Hyper-C for pharma's in-silico discovery and indication expansion budgets.
  • Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI/ML to discover new therapeutics and indications at scale — a directly comparable AI-driven drug discovery platform targeting similar pharma partnerships.
  • Exscientia: Exscientia is an AI-driven pharma company using precision design to accelerate small-molecule drug discovery and indication expansion, offering overlapping value proposition and enterprise pharma client base to Delta4.
  • Insitro: Insitro combines ML with high-throughput experimental biology to discover therapeutics and predict drug behavior — competing for the same enterprise pharma AI-discovery partnerships as Delta4.
  • Atomwise: Atomwise applies deep learning to structure-based drug design and indication prediction, with a heavy pharma partnership focus; directly comparable to Hyper-C's in-silico approach.
  • Valo Health: Valo Health uses AI and patient data to accelerate drug discovery and indication expansion across therapeutic areas, overlapping closely with Delta4's platform-driven pharma services model.

Broad incumbents

  • Isomorphic Labs: Isomorphic Labs (Alphabet-owned) builds AI-first drug discovery platforms and partners with major pharma like Novartis and Lilly; a well-capitalized broader incumbent operating in the same AI drug discovery space as Delta4.

Emerging players

  • Cyclica: Cyclica is a Toronto-based AI drug discovery company applying proteome-wide and polypharmacology approaches to drug repurposing and indication expansion — an emerging player with comparable technology positioning.
  • Owkin: Owkin applies AI to biomedical research and clinical data for pharma and biotech clients, with partial overlap to Delta4's AI-driven drug discovery and disease-mechanism analysis capabilities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Delta4 social profiles

Digital presence

Delta4 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Delta4 leadership team

Management profile

Number of profiles

Profiles1 record

Delta4 funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Delta4 M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Delta4

What does Delta4 do?

Delta4 operates Hyper-C, a proprietary AI-powered computational platform that combines systems biology, computational modeling, and large-scale data analysis to detect undetected relationships between drugs with known safety profiles and identify new therapeutic indications. The company delivers this capability as in-silico drug discovery and indication expansion services to pharmaceutical and biotech clients, applying the platform to accelerate their drug or indication programs.

Is Delta4 a public or private company?

Delta4 is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Delta4 founded?

Delta4 was founded in 2018. It employs 11 to 50 people.

Where is Delta4 based?

Delta4 is headquartered in Vienna, Austria, in the Europe region.

How does Delta4 make money?

One revenue line is on record: drug Discovery Services.

Who are Delta4's main competitors?

Direct peers on record are BenevolentAI, Schrödinger, Recursion Pharmaceuticals, Exscientia, Insitro, Atomwise and Valo Health. Isomorphic Labs is listed as a broad incumbent. Emerging players are Cyclica and Owkin.

Does Delta4 have an API?

No public API is recorded for Delta4.

What industry is Delta4 in?

Delta4's product category is AI Drug Discovery & Indication Expansion. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AutoevolutionOff-Road-Prepped Mercedes G-Wagen Gets Down and Dirty for the Sake of MarketingDelta4x4, an aftermarket off-road parts company, modified a Mercedes G-Wagen with a lift kit raising it 15 centimeters, 35-inch tires, wider fender flares, and a stainless steel bulbar with additional lights for night driving. The modified vehicle was photographed performing off-road maneuvers as a marketing exercise to demonstrate the effectiveness of these relatively simple upgrades. Based on visible side-mounted exhaust tips, the vehicle is believed to be a Mercedes-AMG G 63 powered by a 4.0L bi-turbo V8 producing 850 Nm of torque and 585 ps.openPR.comAI Drug Development Platform Market CAGR 29.90% Future Outlook Led by Insilico Medicine, MindRank, BenevolentAI, Exscientia, Deep Pharma Intelligence, Delta4, DNDi, StandigmThe AI drug development platform market is projected to grow at a CAGR of 29.90% from 2025 to 2032. Growth is driven by the need for efficient drug discovery, with key players including Insilico Medicine, MindRank, BenevolentAI, and Exscientia. The market is expected to surpass a substantial valuation by 2032.Delta4Understanding the Drug Discovery PipelineKurt Herpel, CEO of Delta4, outlines the pharmaceutical drug discovery pipeline, highlighting how artificial intelligence is accelerating the identification of targets and screening of compounds. The article details Delta4's specific use of its Hyper-C platform to repurpose existing drugs for complex diseases such as FSGS and Long-COVID-19 anosmia.